Filing Flows › Bio-Rad Laboratories (BIO) › Q2 2026 › vs Q2 2025
Bio-Rad Laboratories (BIO) Q2 2026 vs Q2 2025 (year over year)
Bio-Rad Laboratories's revenue fell $600K (-0.1%) from $652M in Q2 2025 to $651M in Q2 2026. The biggest changes: Life Science −$10.8M (-4%); Clinical Diagnostics +$10.2M (+3%). Gross margin 53.1% against 53.0% (+0.1 pts).
Bio-Rad Laboratories, Q2 2026: revenue $651M (-0.1% year over year), operating margin 11.2%, net earnings $371M, operating cash flow $98.7M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 53.1% | 53.0% | +0.1 pts |
| Operating margin | 11.2% | 11.8% | -0.7 pts |
| Net margin | 57.1% | 48.8% | +8.3 pts |
| Free cash flow margin | 10.2% | 10.9% | -0.6 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Clinical Diagnostics | $399M | $389M | $10.2M | +3% |
| Life Science | $252M | $263M | −$10.8M | -4% |
| Revenue | $651M | $652M | −$600K | -0.1% |
| Gross profit | $346M | $345M | $500K | +0.1% |
| Cost of revenue | $305M | $306M | −$1.1M | -0.4% |
| Other income, net | $470M | $337M | $133M | +39% |
| Operating profit | $72.6M | $77.1M | −$4.5M | -6% |
| Operating expenses | $273M | $268M | $5.0M | +2% |
| Pre-tax earnings | $542M | $414M | $128M | +31% |
| Research & development | $61.2M | $60.5M | $700K | +1% |
| SG&A | $212M | $208M | $4.3M | +2% |
| Net earnings | $371M | $318M | $53.6M | +17% |
| Income tax | $171M | $96.2M | $74.5M | +77% |
| Share-based compensation | $14.5M | $11.9M | $2.6M | +22% |
| Working capital & other | $287M | $213M | $74.0M | +35% |
| Operating cash flow | $98.7M | $116M | −$17.8M | -15% |
| Free cash flow (OCF − capex) | $66.7M | $70.8M | −$4.1M | -6% |
| Capital expenditures | $32.0M | $45.7M | −$13.7M | -30% |
Questions
How much did Bio-Rad Laboratories's revenue grow year over year in Q2 2026?
Bio-Rad Laboratories's revenue fell $600K (-0.1%) from $652M in Q2 2025 to $651M in Q2 2026.
What drove Bio-Rad Laboratories's revenue change in Q2 2026?
Life Science −$10.8M (-4%); Clinical Diagnostics +$10.2M (+3%).